Safety and Efficacy of Transplantation with Allogeneic Skin Tumors to Treat Chemically-Induced Skin Tumors in Mice

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2016 Sep 3

PMID 27587310

Authors

Zhiwei Zhang

Hua Sun

Jianhua Zhang

Chunlei Ge

Suwei Dong

Zhen Li

Ruilei Li

Xiaodan Chen

Mei Li

Yun Chen

Yingying Zou

Zhongyi Qian

Lei Yang

Jinyan Yang

Zhitao Zhu

Zhimin Liu

Xin Song

Affiliations

Soon will be listed here.

Abstract

BACKGROUND Transplantation with allogeneic cells has become a promising modality for cancer therapy, which can induce graft-versus-tumor (GVT) effect. This study was aimed at assessing the safety, efficacy, and tissue type GVT (tGVT) response of transplantation with allogeneic skin tumors to treat chemically-induced skin tumors in mice. MATERIAL AND METHODS FVB/N and ICR mice were exposed topically to chemicals to induce skin tumors. Healthy ICR mice were transplanted with allogeneic skin tumors from FVB/N mice to test the safety. The tumor-bearing ICR mice were transplanted with, or without, allogeneic skin tumors to test the efficacy. The body weights (BW), body condition scores (BCS), tumor volumes in situ, metastasis tumors, overall survival, and serum cytokines were measured longitudinally. RESULTS Transplantation with no more than 0.03 g allogeneic skin tumors from FVB/N mice to healthy ICR mice was safe. After transplantation with allogeneic skin tumors to treat tumor-bearing mice, it inhibited the growth of tumors slightly at early stage, accompanied by fewer metastatic tumors at 24 days after transplantation (21.05% vs. 47.37%), while there were no statistically significant differences in the values of BW, BCS, tumor volumes in situ, metastasis tumors, and overall survival between the transplanted and non-transplanted groups. The levels of serum interleukin (IL)-2 were significantly reduced in the controls (P<0.05), but not in the recipients, which may be associated with the tGVT response. CONCLUSIONS Our results suggest that transplantation with allogeneic skin tumors is a safe treatment in mice, which can induce short-term tGVT response mediated by IL-2.

References

Bishop M, Fowler D, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg S . Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol. 2004; 22(19):3886-92. DOI: 10.1200/JCO.2004.01.127. View

Bartels C, Rosenberg S, Yang J . Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells. Ann Surg Oncol. 1996; 3(1):67-73. DOI: 10.1007/BF02409054. View

Moore A, RHOADS C, SOUTHAM C . Homotransplantation of human cell lines. Science. 1957; 125(3239):158-60. DOI: 10.1126/science.125.3239.158. View

Brunet M . Cytokines as predictive biomarkers of alloreactivity. Clin Chim Acta. 2012; 413(17-18):1354-8. DOI: 10.1016/j.cca.2012.04.014. View

Walder B, Robertson M, JEREMY D . Skin cancer and immunosuppression. Lancet. 1971; 2(7737):1282-3. DOI: 10.1016/s0140-6736(71)90602-7. View

Kojima R, Kami M, Hori A, Murashige N, Ohnishi M, Kim S . Reduced-intensity allogeneic hematopoietic stem-cell transplantation as an immunotherapy for metastatic colorectal cancer. Transplantation. 2004; 78(12):1740-6. DOI: 10.1097/01.tp.0000146194.36297.4e. View

Diagaradjane P, Yaseen M, Yu J, Wong M, Anvari B . Autofluorescence characterization for the early diagnosis of neoplastic changes in DMBA/TPA-induced mouse skin carcinogenesis. Lasers Surg Med. 2005; 37(5):382-95. DOI: 10.1002/lsm.20248. View

Bregni M, Bernardi M, Ciceri F, Peccatori J . Allogeneic stem cell transplantation for the treatment of advanced solid tumors. Springer Semin Immunopathol. 2004; 26(1-2):95-108. DOI: 10.1007/s00281-004-0164-4. View

Lee J, Nakagiri T, Oto T, Harada M, Morii E, Shintani Y . IL-6 amplifier, NF-κB-triggered positive feedback for IL-6 signaling, in grafts is involved in allogeneic rejection responses. J Immunol. 2012; 189(4):1928-36. DOI: 10.4049/jimmunol.1103613. View

10.

Knight B, Souberbielle B, Rizzardi G, Ball S, Dalgleish A . Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res. 1996; 6(4):299-306. DOI: 10.1097/00008390-199608000-00004. View

11.

Barten M, Rahmel A, Bocsi J, Boldt A, Garbade J, Dhein S . Cytokine analysis to predict immunosuppression. Cytometry A. 2006; 69(3):155-7. DOI: 10.1002/cyto.a.20215. View

12.

Kaur J, Sharma M, Sharma P, Bansal M . Chemopreventive activity of lantadenes on two-stage carcinogenesis model in Swiss albino mice: AP-1 (c-jun), NFkappaB (p65) and P53 expression by ELISA and immunohistochemical localization. Mol Cell Biochem. 2008; 314(1-2):1-8. DOI: 10.1007/s11010-008-9758-9. View

13.

Errington F, Bateman A, Kottke T, Thompson J, Harrington K, Merrick A . Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin Cancer Res. 2006; 12(4):1333-41. DOI: 10.1158/1078-0432.CCR-05-1113. View

14.

Appelbaum F . Hematopoietic cell transplantation as a form of immunotherapy. Int J Hematol. 2002; 75(3):222-7. DOI: 10.1007/BF02982034. View

15.

Ruella M, Kalos M . Adoptive immunotherapy for cancer. Immunol Rev. 2013; 257(1):14-38. DOI: 10.1111/imr.12136. View

16.

Baldwin R . Immunity to transplanted tumour: the effect of tumour extracts on the growth of homologous tumours in rats. Br J Cancer. 1955; 9(4):646-51. PMC: 2073777. DOI: 10.1038/bjc.1955.69. View

17.

Fujii S, Shimizu K, Shimizu T, Lotze M . Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood. 2001; 98(7):2143-51. DOI: 10.1182/blood.v98.7.2143. View

18.

Shenoi M, Iltis I, Choi J, Koonce N, Metzger G, Griffin R . Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy. Mol Pharm. 2013; 10(5):1683-94. PMC: 3744664. DOI: 10.1021/mp300505w. View

19.

Li X, Li R, Qian X, Ding Y, Tu Y, Guo R . Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate. Eur J Pharm Biopharm. 2008; 70(3):726-34. DOI: 10.1016/j.ejpb.2008.06.016. View

20.

Massenkeil G, Roigas J, Nagy M, Wille A, Stroszczynski C, Mapara M . Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant. 2004; 34(4):309-16. DOI: 10.1038/sj.bmt.1704587. View